Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аллергический ринит с позиции аллерголога
Аллергический ринит с позиции аллерголога
Сидорович О.И., Лусс Л.В. Аллергический ринит с позиции аллерголога. Consilium Medicum. 2019; 21 (3): 75–78. DOI: 10.26442/20751753.2019.3.190290
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Аллергический ринит (АР) на сегодняшний день является самым широко распространенным аллергическим заболеванием. Рациональная медикаментозная терапия должна быть направлена на неспецифическое подавление клинических симптомов АР без учета свойств аллергена. Гистамин – основной медиатор аллергического воспаления. Фексофенадин является эффективным и безопасным блокатором H1-гистаминовых рецепторов и препаратом выбора для лечения всех видов АР.
Ключевые слова: аллергический ринит, терапия антигистаминными препаратами, фексофенадин.
Ключевые слова: аллергический ринит, терапия антигистаминными препаратами, фексофенадин.
________________________________________________
Allergic rhinitis (AR) is the most common allergic disease. Rational drug therapy should be aimed at nonspecific suppression of the clinical symptoms of AR without taking into account the properties of the allergen. Histamine is the main mediator of allergic inflammation.
Fexofenadine is an effective H1-antihistamine and a drug of choice for the treatment of all kinds of AR.
Key words: allergic rhinitis, antihistamine therapy, fexofenadine.
Key words: allergic rhinitis, antihistamine therapy, fexofenadine.
Полный текст
Список литературы
1. Scadding GK, Kariyawasam HH, Mirakian R et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47: 856–89.
2. Аллергология. Федеральные клинические рекомендации. Гл. ред. Р.М.Хаитов, Н.И.Ильина. М.: Фармарус Принт Медиа, 2014.
[Allergologiia. Federal'nye klinicheskie rekomendatsii. Gl. red. R.M.Khaitov, N.I.Il'ina. Moscow: Farmarus Print Media, 2014 (in Russian).]
3. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017; 140 (4).
4. Лусс Л.В., Сидорович О.И. Аллергический ринит и аллергический конъюнктивит: механизм взаимосвязи и тактика лечения. Астма и аллергия. 2015; 1: 31–4.
[Luss L.V., Sidorovich O.I. Allergicheskii rinit i allergicheskii kon"iunktivit: mekhanizm vzaimosviazi i taktika lecheniia. Astma i allergiia. 2015; 1: 31–4. (in Russian).]
5. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: 147–334.
6. Church M, Church D. Pharmacology of antihistamines. Indian J Dermatol 2013; 58: 219–24.
7. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус принт, 1998.
[Gushchin I.S. Allergicheskoe vospalenie i ego farmakologicheskii kontrol'. Moscow: Farmarus print, 1998 (in Russian).]
8. Holgate ST, Canonica GW, Simons FE et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003; 33: 1305–24.
9. Axelrod D, Bielory L. Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy 2008; 1: 19–29.
10. Hoechst Marion Roussel. Fexofenadine prescribing information. Kansas City, Missouri, USA.
11. Pratt CM, Mason J, Russell T et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83: 1451–4.
12. Mason J, Reynold R, Rao N. Системная безопасность фексофенадина гидрохлорида. Consilium Medicum. 2000; 2 (5): 202–4.
[Mason J, Reynold R, Rao N. Sistemnaia bezopasnost' feksofenadina gidrokhlorida. Consilium Medicum. 2000; 2 (5): 202–4 (in Russian).]
13. Howarth PH, Stern MA, Roi L et al. Double-blind, placebo-controlled study comparing the efcacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33.
14. Ciprandi G, Cosentino C, Milanese M et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56: 1068–70.
15. Simpson K, Jarvis B. Fexofenadine: A Review of its Use in the Management of Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria. Drugs 2000; 59 (2): 301–21.
16. Efficacy and safety profile of fexofenadine HCI: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003; S69–S77.
17. Инструкция по медицинскому применению препарата Фексадин®.
[Instruktsiia po meditsinskomu primeneniiu preparata Feksadin® (in Russian).]
2. Allergologiia. Federal'nye klinicheskie rekomendatsii. Gl. red. R.M.Khaitov, N.I.Il'ina. Moscow: Farmarus Print Media, 2014 (in Russian).
3. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017; 140 (4).
4. Luss L.V., Sidorovich O.I. Allergicheskii rinit i allergicheskii kon"iunktivit: mekhanizm vzaimosviazi i taktika lecheniia. Astma i allergiia. 2015; 1: 31–4. (in Russian).
5. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: 147–334.
6. Church M, Church D. Pharmacology of antihistamines. Indian J Dermatol 2013; 58: 219–24.
7. Gushchin I.S. Allergicheskoe vospalenie i ego farmakologicheskii kontrol'. Moscow: Farmarus print, 1998 (in Russian).
8. Holgate ST, Canonica GW, Simons FE et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003; 33: 1305–24.
9. Axelrod D, Bielory L. Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy 2008; 1: 19–29.
10. Hoechst Marion Roussel. Fexofenadine prescribing information. Kansas City, Missouri, USA.
11. Pratt CM, Mason J, Russell T et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83: 1451–4.
12. Mason J, Reynold R, Rao N. Sistemnaia bezopasnost' feksofenadina gidrokhlorida. Consilium Medicum. 2000; 2 (5): 202–4 (in Russian).
13. Howarth PH, Stern MA, Roi L et al. Double-blind, placebo-controlled study comparing the efcacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33.
14. Ciprandi G, Cosentino C, Milanese M et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56: 1068–70.
15. Simpson K, Jarvis B. Fexofenadine: A Review of its Use in the Management of Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria. Drugs 2000; 59 (2): 301–21.
16. Efficacy and safety profile of fexofenadine HCI: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003; S69–S77.
17. Instruktsiia po meditsinskomu primeneniiu preparata Feksadin® (in Russian).
2. Аллергология. Федеральные клинические рекомендации. Гл. ред. Р.М.Хаитов, Н.И.Ильина. М.: Фармарус Принт Медиа, 2014.
[Allergologiia. Federal'nye klinicheskie rekomendatsii. Gl. red. R.M.Khaitov, N.I.Il'ina. Moscow: Farmarus Print Media, 2014 (in Russian).]
3. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017; 140 (4).
4. Лусс Л.В., Сидорович О.И. Аллергический ринит и аллергический конъюнктивит: механизм взаимосвязи и тактика лечения. Астма и аллергия. 2015; 1: 31–4.
[Luss L.V., Sidorovich O.I. Allergicheskii rinit i allergicheskii kon"iunktivit: mekhanizm vzaimosviazi i taktika lecheniia. Astma i allergiia. 2015; 1: 31–4. (in Russian).]
5. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: 147–334.
6. Church M, Church D. Pharmacology of antihistamines. Indian J Dermatol 2013; 58: 219–24.
7. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М.: Фармарус принт, 1998.
[Gushchin I.S. Allergicheskoe vospalenie i ego farmakologicheskii kontrol'. Moscow: Farmarus print, 1998 (in Russian).]
8. Holgate ST, Canonica GW, Simons FE et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003; 33: 1305–24.
9. Axelrod D, Bielory L. Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy 2008; 1: 19–29.
10. Hoechst Marion Roussel. Fexofenadine prescribing information. Kansas City, Missouri, USA.
11. Pratt CM, Mason J, Russell T et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83: 1451–4.
12. Mason J, Reynold R, Rao N. Системная безопасность фексофенадина гидрохлорида. Consilium Medicum. 2000; 2 (5): 202–4.
[Mason J, Reynold R, Rao N. Sistemnaia bezopasnost' feksofenadina gidrokhlorida. Consilium Medicum. 2000; 2 (5): 202–4 (in Russian).]
13. Howarth PH, Stern MA, Roi L et al. Double-blind, placebo-controlled study comparing the efcacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33.
14. Ciprandi G, Cosentino C, Milanese M et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56: 1068–70.
15. Simpson K, Jarvis B. Fexofenadine: A Review of its Use in the Management of Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria. Drugs 2000; 59 (2): 301–21.
16. Efficacy and safety profile of fexofenadine HCI: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003; S69–S77.
17. Инструкция по медицинскому применению препарата Фексадин®.
[Instruktsiia po meditsinskomu primeneniiu preparata Feksadin® (in Russian).]
________________________________________________
2. Allergologiia. Federal'nye klinicheskie rekomendatsii. Gl. red. R.M.Khaitov, N.I.Il'ina. Moscow: Farmarus Print Media, 2014 (in Russian).
3. Brożek JL, Bousquet J, Agache I et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines – 2016 Revision. J Allergy Clin Immunol 2017; 140 (4).
4. Luss L.V., Sidorovich O.I. Allergicheskii rinit i allergicheskii kon"iunktivit: mekhanizm vzaimosviazi i taktika lecheniia. Astma i allergiia. 2015; 1: 31–4. (in Russian).
5. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108: 147–334.
6. Church M, Church D. Pharmacology of antihistamines. Indian J Dermatol 2013; 58: 219–24.
7. Gushchin I.S. Allergicheskoe vospalenie i ego farmakologicheskii kontrol'. Moscow: Farmarus print, 1998 (in Russian).
8. Holgate ST, Canonica GW, Simons FE et al. Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003; 33: 1305–24.
9. Axelrod D, Bielory L. Fexofenadine hydrochloride in the treatment of allergic disease: a review. J Asthma Allergy 2008; 1: 19–29.
10. Hoechst Marion Roussel. Fexofenadine prescribing information. Kansas City, Missouri, USA.
11. Pratt CM, Mason J, Russell T et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999; 83: 1451–4.
12. Mason J, Reynold R, Rao N. Sistemnaia bezopasnost' feksofenadina gidrokhlorida. Consilium Medicum. 2000; 2 (5): 202–4 (in Russian).
13. Howarth PH, Stern MA, Roi L et al. Double-blind, placebo-controlled study comparing the efcacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 927–33.
14. Ciprandi G, Cosentino C, Milanese M et al. Fexofenadine reduces nasal congestion in perennial allergic rhinitis. Allergy 2001; 56: 1068–70.
15. Simpson K, Jarvis B. Fexofenadine: A Review of its Use in the Management of Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria. Drugs 2000; 59 (2): 301–21.
16. Efficacy and safety profile of fexofenadine HCI: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003; S69–S77.
17. Instruktsiia po meditsinskomu primeneniiu preparata Feksadin® (in Russian).
Авторы
О.И.Сидорович*, Л.В.Лусс
ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*olga_smail@yahoo.com
ФГБУ «Государственный научный центр "Институт иммунологии"» ФМБА России, Москва, Россия
*olga_smail@yahoo.com
________________________________________________
Olga I. Sidorovich*, Liudmila V. Luss
National Research Center – Institute of Immunology, Moscow, Russia
*olga_smail@yahoo.com
National Research Center – Institute of Immunology, Moscow, Russia
*olga_smail@yahoo.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.